Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles.
biomarkers in brain metastases
immunotherapy in brain metastases
targeted therapy in brain metastases
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
12
2021
Statut:
epublish
Résumé
Brain metastases (BM) present a common cause of mortality and morbidity in several metastatic cancer entities. New therapeutic developments during the last decades, including targeted and immune-related therapies, have shown considerable extra- and intracranial response rates in specific subgroups of BM patients. However, differences in the molecular alteration in the BM tumor tissue compared to extracranial tumors leads to heterogeneous therapeutic responses. Therefore, an accurate molecular analyzation of BM tissue, if possible, has become an essential part in therapeutic decision making in BM patients. The concordance of predictive molecular biomarkers between multiple sites including extracranial and intracranial tumor tissue have been analyzed for some but not all biomarkers routinely applied in modern precision medicine approaches. In the present review, we summarize the current evidence of predictive biomarkers for personalized therapy approaches in the treatment of parenchymal BM.
Identifiants
pubmed: 34859231
doi: 10.1093/noajnl/vdab105
pii: vdab105
pmc: PMC8633753
doi:
Types de publication
Journal Article
Langues
eng
Pagination
v35-v42Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Clin Lung Cancer. 2014 Nov;15(6):470-4
pubmed: 25087901
Ann Oncol. 2020 Jun;31(6):674-696
pubmed: 32199930
J Clin Oncol. 2004 Sep 1;22(17):3608-17
pubmed: 15337811
J Clin Oncol. 2018 Sep 20;36(27):2804-2807
pubmed: 29939840
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
J Thorac Oncol. 2011 Jul;6(7):1149-51
pubmed: 21847039
Semin Neurol. 2018 Feb;38(1):95-103
pubmed: 29548056
J Neurooncol. 2016 Oct;130(1):19-29
pubmed: 27436101
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Neurooncol. 2014 Jun;118(2):425-426
pubmed: 24760415
Chin J Cancer. 2011 May;30(5):287-92
pubmed: 21527061
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Acad Radiol. 2005 Oct;12(10):1232-40
pubmed: 16179200
Neuro Oncol. 2020 Aug 17;22(8):1173-1181
pubmed: 31970416
Ann Oncol. 2020 Nov;31(11):1435-1448
pubmed: 32763453
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
J Thorac Oncol. 2014 Feb;9(2):154-62
pubmed: 24419411
Lung Cancer. 2018 Feb;116:62-66
pubmed: 29413052
Sci Rep. 2017 Aug 31;7(1):10255
pubmed: 28860576
Ann Oncol. 2018 Jan 1;29(suppl_1):i38-i46
pubmed: 29462257
Oncotarget. 2020 Aug 18;11(33):3118-3128
pubmed: 32913556
Ann Oncol. 2018 Jun 1;29(6):1409-1416
pubmed: 29668860
J Natl Cancer Inst. 2018 Jun 1;110(6):568-580
pubmed: 29315431
J Clin Oncol. 2012 Jul 10;30(20):2522-9
pubmed: 22614978
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Lung Cancer. 2013 Jun;80(3):278-83
pubmed: 23453647
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
Chin Clin Oncol. 2015 Jun;4(2):21
pubmed: 26112807
J Thorac Oncol. 2016 Jul;11(7):964-75
pubmed: 27117833
Acta Neuropathol. 2014 Dec;128(6):879-91
pubmed: 25287912
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
J Neurooncol. 2013 Jan;111(1):1-10
pubmed: 23086434
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Breast Cancer Res. 2012 Aug 16;14(4):R119
pubmed: 22898337
Expert Rev Anticancer Ther. 2021 Mar;21(3):325-339
pubmed: 33196341
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Curr Treat Options Neurol. 2017 Apr;19(4):13
pubmed: 28374234
Lancet Oncol. 2013 Jan;14(1):64-71
pubmed: 23122784
Adv Ther. 2019 Oct;36(10):2600-2617
pubmed: 31432460
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
J Mol Diagn. 2014 Sep;16(5):558-563
pubmed: 24994671
J Neurooncol. 2014 Oct;120(1):147-54
pubmed: 25098698
Clin Exp Metastasis. 2015 Oct;32(7):729-37
pubmed: 26303828
Nat Rev Neurosci. 2007 Aug;8(8):610-22
pubmed: 17643088
Int J Cancer. 2006 Sep 15;119(6):1491-4
pubmed: 16642476
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Thorac Cancer. 2020 Mar;11(3):588-593
pubmed: 31944608
Transl Lung Cancer Res. 2018 Dec;7(6):639-646
pubmed: 30505708
Cells. 2020 Oct 31;9(11):
pubmed: 33142852
J Neurooncol. 2019 Oct;145(1):85-95
pubmed: 31456143
Front Oncol. 2018 Jul 18;8:270
pubmed: 30073150
CNS Drugs. 2013 Feb;27(2):121-34
pubmed: 23239265
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Mol Clin Oncol. 2013 Jul;1(4):575-581
pubmed: 24649213
Bosn J Basic Med Sci. 2020 Aug 03;20(3):329-335
pubmed: 31999935
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
Ann Oncol. 2009 Apr;20(4):696-702
pubmed: 19088172
Lung Cancer. 2013 Sep;81(3):347-353
pubmed: 23806795
J Thorac Oncol. 2019 Jul;14(7):1244-1254
pubmed: 30780002
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Breast Cancer Res Treat. 2017 Aug;164(3):581-591
pubmed: 28493046
J Thorac Oncol. 2016 Mar;11(3):380-90
pubmed: 26823294
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
ESMO Open. 2018 Jan 26;3(1):e000262
pubmed: 29387475
Lung Cancer. 2019 Feb;128:105-112
pubmed: 30642441
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716